1-11-2009 | PharmaCell BV appoints new CEO

Maastricht, November 1^st 2009

PharmaCell B.V. has appointed Mr. Alexander Vos as Chief Executive Officer, effective November 1^st 2009. PharmaCell is a biopharmaceutical company active in human cell and tissue culturing and related services, based in Maastricht (Netherlands).

Mr. Vos has 20 years of leadership experience in the pharma and biotech industry. He joins from PAION AG, where he was a Member of the Management Board (“Vorstand”) and Chief Operating Officer from 2004 onwards. PAION is a clinical stage biopharmaceutical company based in Aachen (Germany) and Cambridge (UK) that is listed on the Frankfurt Stock Exchange.

Mr. Vos started his career at McKinsey & Co. as a strategy consultant in their international pharmaceutical practice. Subsequently, at Genzyme Therapeutics Europe he held executive positions as European Marketing Director and Director of Business Development, before assuming global responsibility for its joint venture with Pharming N.V. From 2000 to 2004, Mr. Vos served as Chief Executive Officer of MediService AG (Switzerland), one of the leading specialty pharmacy service companies in Europe, which was successfully sold to Galenica AG. Mr. Vos holds a M.Sc. in Pharmacy and Pharmacology from the University of Amsterdam and an MBA from the Stanford Graduate School of Business.

Mr. Casper Bruens, Chairman of the Supervisory Board, comments: “We view human Cell Therapy as the next area of growth in the biomedical and pharma sectors and we see the Maastricht region becoming a centre of excellence in Cell Therapy and Tissue Engineering. We feel that Mr. Vos will form an excellent team with PharmaCell’s CTO René Lardenoije and will be very important in realizing further growth and defining the next strategic steps“.

Alexander Vos adds: “I am excited to join the team at PharmaCell at this important point in time. The expertise of PharmaCell has become increasingly well recognized in the field of cell-based therapies and I have been impressed with the progress the company has made so far. I am thrilled to start working with the PharmaCell team to further capitalize on the opportunities in this rapidly advancing area”.